Innovent Biologics aiming for US$422mn Hong Kong IPO

Innovent Biologics, a Chinese biopharmaceutical firm focused on the development of drugs to combat cancer and autoimmune diseases, is aiming to raise US$422mn for its Hong Kong IPO, Reuters reported
In April, Innovent announced that it had raised $150mn in its Series E funding round, led by Capital Group Private Markets.
Reuters said that Innovent’s IPO could be Hong Kong’s largest in the biotech industry this year.
The Hong Kong government introduced new legislation in April this year to encourage early-stage pharmaceutical firms to list on the stock exchange, enabling biotech companies that have yet to turn a profit or generate revenue to go public.
See more:
Thus far, Reuters said, biotech firms listing under this legislation have not performed well, and it added that “a market rout last week drove Tencent Music Entertainment to postpone its own IPO.”
According to Reuters’ sources, Innovent has secured 10 cornerstone investors with a combined commitment to $245mn in shares despite not yet having any drugs approved for commercial sale.
The firm said on 15 October that it has received IND approval to initiate trials for a new combination therapy against various lung and liver cancers, which account for around a third of all cancer cases in China.

Featured Articles

Exec interview: Brook Sims, COO, MAC Diversity Recruiters

Passionate about helping others find their voice, diversity leader and COO Brook Sims talks powerful leadership, diverse teams and being a change agent

Best new books that will make you a better leader

From inspiring CEO memoirs to strategic guides, these new books dish up plenty of principles, strategies, and anecdotes to help you become a better boss

5 Mins With: Jeff Li, founder and CEO of Shoplazza

Named in Fortune China’s 40 under 40 for 2022, former Baidu head Jeff Li is the entrepreneurial founder and CEO of ecommerce platform Shoplazza

Workplace special – the changing nature of the office

Leadership & Strategy

Meet Shanique Bonelli-Moore, DEI leader at Clorox


Forterro CEO Dean Forbes – inspirational leadership

Leadership & Strategy